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on hourly labour costs is used for productivity costs per working day/hour.
RESULTS:Vacancy durations estimated in 2009 for The Netherlands, Belgium, Ger-
many, France, the UK, Norway and Sweden range between 40-80 days. Regression
analysis of the vacancy durations shows that, there is a strong negative relation-
ship between vacancy durations and unemployment rates. When unemployment
increases, vacancy durations and hence friction period decline. We also find that
an increase in the vacancy rate (the ratio of the stock of vacancies to total labor
force) has a positive effect on vacancy durations which can be explained by the
congestion provoked by the increase in the number of vacancies competing in the
labor market.CONCLUSIONS:This paper provides estimates on vacancy durations,
friction periods and the price component in order to calculate the friction costs. For
seven European countries, we present empirical estimates to use the friction cost
method in a practical way which can improve more uniform analysis of productiv-
ity costs in economic evaluations of diseases. Our regression results confirm the
validity of estimated vacancy durations which are necessary to calculate the length
of friction period and friction costs.
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BREAST AND PROSTATE CANCER PRODUCTIVITY COSTS: A COMPARISON OF
THE HUMAN CAPITAL APPROACH AND FRICTION COST APPROACH
Hanly P, Timmons A, Walsh P, Sharp L
National Cancer Registry Ireland, Cork, Ireland
OBJECTIVES: Productivity costs constitute a substantial proportion of the total
societal costs associated with cancer. Cancer patients may leave the workforce
permanently post-diagnosis, take time off during treatment and/or return to work
with reduced hours or die prematurely; the associated productivity costs have
rarely been considered. We applied the dominant human capital approach (HCA)
and the emerging friction cost approach (FCA) to estimate breast and prostate
cancer productivity costs in Ireland in 2008. METHODS: Data from a survey of
breast and prostate cancer patients (n358) was combined with population-level
survival estimates (from the population-based National Cancer Registry) and a
national wage dataset to calculate costs of temporary disability (cancer-related
work absence), permanent disability (workforce departure, reduced working hours)
and premature mortality, using the HCA and FCA. Sensitivity analyses were con-
ducted for key parameters: GNP growth and discount rates for HCA and friction
period and labour elasticity for FCA. RESULTS: According to the HCA, productivity
costs per person amounted to €193,425 for breast and €109,154 for prostate cancer.
FCA per person costs were €8103 for breast and €8205 for prostate cancer. The HCA
generated higher costs for younger patients (breast cancer) due to greater lifetime
earning potential. In contrast FCA resulted in higher productivity costs for older
male patients (prostate) commensurate with higher earning capacity over a shorter
time period. Reduced working hours post-cancer was a key driver of total HCA
productivity costs. HCA costs were sensitive to assumptions about discount and
growth rates. FCA costs were sensitive to assumptions about the friction period.
CONCLUSIONS: This study highlights the importance of choosing the correct val-
uation method for chronic long-term illnesses such as cancer, being explicit about
assumptions, and considering a range of cost sub-components, including those
due to reduced working hours.
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OBJECTIVES: The aim of this study was to estimate the impact of pandemic
Influenza A H1N1/2009 in terms of patient’s health care services utilization,
work absenteeism and associated costs. METHODS: Longitudinal, descriptive,
multi-centre study of in- and outpatients with confirmed diagnosis of influenza A
H1N1/2009 in Spain. Sociodemographic and clinical characteristics were gathered
together with health and social resources use, at the admission or primary visit,
and also after recovery. Cost analyses were conducted under a social perspective,
incidence focus and with a temporal horizon of 3 months. Unit cost of resources
was imputed to calculate the mean cost by inpatient and outpatient. A sensitivity
analysis with variations was conducted (Monte Carlo simulation). RESULTS:A total
of 172 inpatients and 224 outpatients were included, 20% and 30% of whom, re-
spectively, were under 17 years old; 12% of inpatients were at ICU, 7.8 (SD3.7)
days, on average, and stayed in general wards for 9.6 (SD7.7) additional days. The
rest of inpatients had a mean hospitalization length of 5 (SD4.4) days. The most
frequently used ambulatory health resource was the primary care medical assis-
tance; 43.8% of inpatients and 66.1% of outpatients were employed, of whom 100%
(inpatients) and 91.7% (outpatients) went on sick leave. Absenteeism length was of
30 (SD20.7) days for inpatients and 9 (SD6.3) for outpatients. Caregivers of 21.7%
of the inpatients also led work absenteeism, as well as the 8.5% of those of outpa-
tients. The proportion of indirect cost for general-ward-inpatients was 30%. This
percentage ascended to 77% in the case of outpatients. The mean costs per inpa-
tient were €6,236 (CI95%1,384–14,623) and €940 (CI95%66–3,064) per outpatient.
CONCLUSIONS: Hospitalizations represents the highest economic cost, together
with work absenteeism. Since only a marginal proportion of influenza cases are
hospitalized, productivity losses emerge as the most important impact of the dis-
ease.
PODIUM SESSION I:
IN-DEPTH STUDIES ON DIFFERENCES AND OPPORTUNITIES IN PRICING AND
MARKET ACCESS
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KEY MARKET ACCESS DRIVERS FOR A SUCCESSFUL HEALTH TECHNOLOGY
APPRAISAL OUTCOME – THE CASE OF RHEUMATOID ARTHRITIS
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1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3Novo Nordisk
A/S, Søborg, Denmark, 4University Claude Bernard Lyon 1, Lyon, France
OBJECTIVES: This study evaluated several recent drug launches in Rheumatoid
Arthritis (RA) to determine which factors contribute to Health Technology Ap-
praisal (HTA) outcomes. METHODS: We reviewed the appraisals of RA drugs
launched in the last five years by the following HTA agencies: England (NICE),
Scotland (SMC), Sweden (TLV), France (HAS), Spain (CAHTA/CANM) and The Neth-
erlands (CVZ). We analysed the proportion of recommended, restricted and not
recommended appraisals and the reasons for these decisions. A subsequent anal-
ysis of the evidence and arguments developed in the appraisal by the HTA agency
was performed. We classified them as clinical, economic, humanistic or social, in
addition we analysed the outcome by country and drug. RESULTS: The listed HTA
agencies issued a total of 25 appraisals (first appraisal, indication expansion and
re-appraisal) for the 4 drugs analysed (certolizumab, golimumab, tocilizumab and
abatacept). There were 9 recommendations for use (36%), 13 restricted use deci-
sions (52%) and 3 decisions to not recommend for use (12%). In 96% of the cases, the
study design (population, add-on vs. monotherapy, duration of trials, comparators
etc.) were systematically quoted as the primary reason for the HTA agency deci-
sion. In 44% of these cases, in addition to design issues, the lack of convincing
health economic data was mentioned. The reasons for favourable recommenda-
tions were 100% clinical and 56% economic, for restricted 100% clinical and 31%
economic and in case of non-recommendation 67% clinical and 67% economic.
CONCLUSIONS: The primary reason for restriction and non-recommendation are
clinical design issues. Consequently it is recommended that manufacturers incor-
porate payer’s expectations in their development plan early enough to influence
trial design and to collect robust health economic evidence.
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OBJECTIVES: The recent UK value-based pricing (VBP) consultation proposes that
burden of illness, therapeutic improvement/innovation and wider societal benefits
are evaluated in addition to cost-effectiveness. This study explored attitudes
among industry, academia and UK National Health Service (NHS) stakeholders to
the proposed VBP framework, with a focus on how to define the burden of illness
component. METHODS: Relevant literature was identified via a manual search to
assess the use of VBP methodologies in other countries and potential burden of
illness (BOI) criteria. In-depth, semi-structured 40-minute telephone interviews
were then undertaken with 20 experts identified in UK academic centres, the phar-
maceutical industry and the NHS. Discussions explored perspectives on VBP and in
particular how to define and evaluate BOI. RESULTS: Proposed definitions for BOI
varied significantly. Industry representatives wanted the flexibility to use a broad,
variable set of criteria, while academic and NHS stakeholders wanted practical,
consistent evaluation criteria with the emphasis on ensuring benefits are not ‘dou-
ble-counted’. Stakeholder input was used to develop a framework for assessing BOI
comprising disease severity, quality of life impact, treatment availability and per-
formance of existing treatments. Qualitative grading scales for each of the criteria
were proposed. While each stakeholder group broadly endorsed VBP objectives, the
research highlighted various concerns regarding its implications. In particular, the
need for clear government policy and guidance, further development of acceptable
evaluation methodologies (including criteria weightings), and enhanced pharma-
ceutical development processes to ensure evidence of sufficient quality is gener-
ated to support evaluation of product value (both at launch and over time).
CONCLUSIONS: There appears to be sufficient common ground to develop a BOI
assessment framework that is acceptable to both industry and NHS stakeholders.
We propose a relatively simple model that could form the basis for further research
and discussion, with special attention to addressing the implementation chal-
lenges.
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1University of Cambridge, Cambridge, UK, 2Double Helix Consulting Group, London, UK
OBJECTIVES: The Pharmaceutical Market Restructuring Act (AMNOG) came into
action in Germany January 2011 with the aim of containing rising health care
expenditure, notably by introducing mandatory benefit assessments and price ne-
gotiation for all new innovative pharmaceuticals. The impact of the reform for the
pharmaceutical industry is predicted to be at its highest with repercussions beyond
the country’s borders, due to Germany’s strategic importance in the European
market. This project aimed to identify the challenges and opportunities created for
the industry in terms of pricing and market access of innovative pharmaceuticals.
METHODS: The impact was measured from three angles by developing hypotheses
and testing them thanks to a series of exploratory interviews with pharmaceutical
companies and Market access stakeholders. RESULTS: Results obtained project
that the impact of the reform for the industry will be very high, increasing the
importance of national stakeholders, altering the cost, time and strategy for mar-
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ket access as well as potentially leading to significant price reductions. What do
these changes mean for the industry? What are the main challenges and opportu-
nities for companies and how can they best adapt? Many questions remain to be
determined. Yet AMNOG sets the scene for a new Market access process in Ger-
many, for which challenges can be foreseen. The industry will need to acquire new
skills to interact with national Market access stakeholders, develop internal effi-
cient processes to compile Benefit Dossiers, adapt the European launch sequence
as well as investigate new Market access strategies, for example targeting sub-
target population groups to demonstrate higher additional benefit or leveraging
Phase IV data. CONCLUSIONS: Industry needs to prepare itself for developing their
launch and commercial strategies in Germany as Germany is a key market from
revenue, price referencing and credibility perspective.
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OBJECTIVES: Spending on prescription drugs in key OECD countries has increased
by 50% or more in the last ten years, raising questions about overall system sus-
tainability. The study analyses possible reasons for differences in prices and vol-
umes consumed across key OECD countries, taking into account national differ-
ences in pharmaceutical policy and regulatory mechanisms.METHODS: Panel data
modelling is used to investigate the effect of pharmaceutical pricing and reim-
bursement regulations, drug promotion, drug use, and competition on price levels.
Data are from IMS Health and the US Federal Supply Schedule and include top-50
selling on patent and generic prescription drugs used in the study countries. Reg-
ulatory variables are included as dummy variables in the model. RESULTS: Prelim-
inary results suggest that: a) cross-country price comparisons are only meaningful
if the right prices are compared in each case. Here, we demonstrate how significant
price differences are when ex-factory prices are compared and how these differ-
ences narrow down significantly when public prices are compared across countries;
b) It seems that price differences of originator brands between the US and Europe
have been exaggerated; generic prices are very often significantly lower in the US
than in other countries; c) Cross-country public price differences and cross-country
ex-factory price differences are not the same across the study countries; d) Off-
patent originator brands account for a significant proportion of the price variation
between US and the other study countries; e) Pricing regulation accounts for a
considerable proportion of the variation in prices across the study countries; and f)
Distribution and taxation can contribute significantly to the total cost of prescrip-
tion medicines that health insurers pay. CONCLUSIONS: Price differences are sig-
nificant when ex-factory prices are compared but are significantly reduced when
public prices are compared across countries. Regulation, distribution, and taxes are
key contributors to the total cost of medicines paid by insurers.
PODIUM SESSION II:
MIXED TREATMENT COMPARISONS MATURE, IN ABSENCE OF SUFFICIENT
HEAD-TO-HEAD COMPARISONS
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OBJECTIVES: Bayesian network meta-analyses incorporate prior distributions
(“priors”) that are updated with new evidence to generate posterior distributions.
The use of uninformative (vague) priors minimizes potential biases and promotes
transparency. Guideline developers have recommended values for uninformative
priors for binary outcomes. For continuous outcomes, the choice of priors is scale-
dependent. In networks with heterogeneity and few studies, a more informed prior
for estimation of between-studies standard deviation () is justifiable, yet may
impose subjectivity. Using a network meta-analysis of seven studies estimating
the efficacy of three renal transplant immunosuppressants (tacrolimus, cyclospo-
rine and belatacept), we estimated the impact of varying priors for  to the relative
effect sizes. METHODS: We established a clinically-plausible range for an uninfor-
mative prior distribution of . We then derived estimates for the indirect compar-
ison of belatacept and tacrolimus expressed as true mean difference (TMD) in renal
function, expressed as glomerular filtration rate (GFR; mL/min/1.73m2); 95% cred-
ible intervals (CrI); and model fit (residual deviance and deviance information cri-
terion). We conducted sensitivity analyses using more informed priors: half the
uninformative range; a data-driven approach; half the data-driven range; and, as
an extreme, a fixed-effect model (  0). RESULTS: Using the uninformative uni-
form prior, U(0,20), the estimated TMD in GFR was 9.84 higher for belatacept than
tacrolimus. This had the best model fit and the widest 95% CrI (1.97, 20.51). As the
upper bound of the prior distribution was restricted, the 95% CrIs narrowed yet the
model fit degraded. The point estimate was stable. The narrowest informed prior
was U(0,3) (TMD 9.84; 95% CrI 4.89, 15.90).CONCLUSIONS: In this analysis, the point
estimates for TMD in GFR consistently favored belatacept, yet the CrIs and model fit
were affected by the choice of prior for . Given the subjectivity in selecting priors
for continuous outcomes, transparent reporting is essential.
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THE USE OF CONTINUOUS DATA VERSUS CATEGORICAL DATA IN MTC: THE
CASE OF HAQ MULTIPLIER IN RHEUMATOID ARTHRITIS
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OBJECTIVES: Each of the tumour necrosis factor alpha antagonists (anti-TNF-)
available to treat rheumatoid arthritis have demonstrated considerable efficacy in
placebo controlled trials, but few head-to-head comparisons exist to date. This
work estimates the relative efficacy among licensed anti-TNFs and highlights the
advantages of continuous outcome measures in mixed treatment comparison
models. METHODS: Relative efficacy was estimated using Bayesian mixed treat-
ment comparison (MTC) models. Three different outcome measures were used;
Risk ratios of achieving an ACR20 and ACR50 response (binomial outcomes) and the
percentage improvement in HAQ score (continuous outcome). Five anti-TNF- an-
tagonists were included in the analysis; adalimumab, infliximab, etanercept, goli-
mumab and certolizumab. RESULTS: All anti-TNF agents show a significant im-
provement over placebo across all outcome measures. The HAQ model outcomes
provide evidence that all anti-TNF agents show improvement over infliximab. This
effect is not found with the ACR outcomes for adalimumab and golimumab. Fur-
thermore, the HAQ model indicates a superiority of etanercept over adalimumab.
The evidence of certolizumab pegol providing improvement over golimumab,
which can be found in the ACR outcomes, is not apparent in the HAQ outcomes.
CONCLUSIONS: Continuous outcome measures make better use of the complete
data than binomial measures and are therefore more sensitive to change. The
results suggest that it may be the case, in mixed treatment comparison models,
where the essence lies in detecting differences, a continuous outcome measure is
more appropriate. Its enhanced sensitivity to change increases the power of the
model to detect differences among treatments. The HAQ multiplier provides one
such measure, but others exist.
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A BAYESIAN APPROACH TO MODEL SELECTION PROCEDURES WITHIN MIXED
TREATMENT COMPARISON FRAMEWORK
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OBJECTIVES: Model fit in Bayesian mixed treatment comparisons (MTC) is often
assessed by the deviance information criterion (DIC). In some cases DIC is not
conclusive. Our aim was to compare DIC with an alternative approach: formal
Bayesian model comparison by estimating the posterior distribution over the
model space. METHODS: DIC is a criterion which combines posterior mean of the
deviance and deviance of posterior means. Models with lower DIC should be pre-
ferred, however if the difference in DICs is small the decision should not be based
solely on DIC. Marginal data density (MDD) expresses probability of observing given
dataset. Decision rule based on Bayesian model comparison is that the model with
highest a posteriori probability should be chosen. Data from few systematic reviews
indexed in Pubmed were extracted in order to find MTC datasets for which DICs for
fixed (FEM) and random effects models (REM) are very similar. Two continuous
variables datasets were chosen. Posterior distributions and DICs were estimated in
WinBugs. The Newton-Raftery estimator of MDD was implemented in Java, to-
gether with the Gibbs sampler. In both cases, in which DIC was not conclusive, two
a priori structures over the model space were assumed: an uniform distribution and
one penalizing the models for the excessive number of parameters. RESULTS: In
the first dataset difference in DICs was 1.3 (in favor REM), in the second dataset this
difference was 2,0 (in favor FEM). In both cases REM turned out to have a higher
value of MDD. Although a priori odds ratio was around 100:1 for FEM, the posterior
distribution was in every case close to have probability of one (0.9999) for the REM.
CONCLUSIONS: Decision about model selection should include tools of formal
model comparison, as conclusions coming from it are always interpretable and
coherent within Bayesian inference.
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MIXED TREATMENT COMPARISONS USING AGGREGATE- AND INDIVIDUAL-
PARTICIPANT LEVEL DATA: AN EFFICIENT USE OF EVIDENCE FOR COST-
EFFECTIVENESS MODELLING
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1University of York, York, North Yorkshire, UK, 2University of Leicester, Leicester, Leicestshire,
UK
OBJECTIVES: Cost-effectiveness analysis must use all relevant sources of evi-
dence to inform reimbursement decisions. Mixed treatment comparisons (MTC)
extends the traditional pair-wise meta-analytic framework to facilitate the syn-
thesis of information on more than two interventions. While most MTCs use
aggregate data (AD), a proportion of the evidence base might be available at the
individual level (IPD). This paper develops novel statistical models aimed to
fully exploit the existing data, regardless of the format (i.e. AD or IPD).
METHODS: We develop a series of novel Bayesian statistical MTC models to allow
for the simultaneous synthesis of IPD and AD, while considering study and indi-
vidual level covariates, and use these to inform a decision model. RESULTS: The
effectiveness of home safety education and the provision of functioning smoke
alarms (binary outcome – Yes/No) for the prevention of childhood injuries in the
household was used as a motivating example. Case study included 20 trials (11 AD,
9 IPD), summing up to 11,500 participants. Seven strategies were defined and a
network of evidence was constructed. Irrespective of the evidence format used, all
models which did not consider information on covariate(s) showed equivalent
results, i.e. more intensive interventions (providing education, equipment (with
fitting) and home inspection) were more effective (OR vs usual care of 4.5 (95%
A237V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
